Company Description

Zehna Therapeutics is developing non-bactericidal inhibitors of selected gut microbial enzymes clinically and mechanistically linked with cardiometabolic diseases. Their lead compounds inhibit the gut microbial enzyme CutC lyase, preventing the conversion of dietary choline to trimethylamine (TMA) and subsequently to trimethylamine N-oxide (TMAO) within the host.